front 1 T cell CTLA interaction with APC B7 activates T cells? | back 1 False - inactivates |
front 2 T cell PD-1 activation by PD-L1 inactivates T cells by blocking CD28/TCR-dependent signaling? | back 2 True |
front 3 Cold tumors are not likely to trigger a strong immune response due to the exclusion of T cells in the microenvironment? | back 3 True |
front 4 Checkpoint inhibitors would be especially useful in what type of tumor? | back 4 Cold |
front 5 Which mAb targets CTLA-4 to block T cell-tumor interaction? | back 5 Ipilimumab |
front 6 Which mAb targets PD1? | back 6 Nivolumab, Pembrolizumab |
front 7 ADE of Nivolumab: | back 7 dyspnea, musculoskeletal pain |
front 8 ADE of Pembrolizumab: | back 8 arthralgia, diarrhea, pruritis |
front 9 Which mAb targets PD1? | back 9 Atezolizumab, Durvalumab |
front 10
Hypo/hyper-thyroidism, | back 10 Atezolizumab, Durvalumab |
front 11 Capillary leak syndrome is associated with what agent? | back 11 Aldesleukin |
front 12 Which agent is a recombinant IL-2 that induces T-cell and NK cell proliferation? | back 12 Aldesleukin |
front 13
Patients should have normal renal and hepatic function; close
supervision | back 13 Aldesleukin |
front 14 What is the target of Interferon Alfa 2B? | back 14 IFNAR2 - activates JAK/STAT in T cells |
front 15 Myelosuppression is associated with which agent? | back 15 Interferon Alfa-2B |
front 16 Lenalidomide increases the production of what? | back 16 IL-2 IFNy |
front 17 Sipuleucel-T reprograms a patient's PBMCs by exposure to: | back 17 PSA PAP |
front 18 Which vaccine increases a patient's GM-CSF? | back 18 T-VEC Talimogene Laherparepvec |
front 19 Which agents are used for CAR-T therapy? | back 19 Tisagenlecleucel, Axicabtagene Ciloleucel |
front 20 MOA of CAR-T therapy? | back 20 T cell transfer to make a patient OVER-EXPRESS CD28 TCR that interacts with CD19 |
front 21 CAR-T induced cytokine release is associated with what agent? | back 21 IL-6 |
front 22 What two agents can be used to treat CRS? | back 22 siltuximab and tocilizumab |
front 23 Which two agents are anti-CD20 antibodies? | back 23 Rituximab, Obinutuzumab |
front 24 Infusion reactions can be lethal with what agents? | back 24 Anti-CD20 agents (Rituximab, Obinutuzumab) |
front 25 Which CD-20 agent has the lowest risk of infusion reactions? | back 25 Rituximab |
front 26 Which two agents are radioisotope-conjugated anti-CD20 antibodies? | back 26
|
front 27 Which agent is an anti-CD19 antibody? | back 27 Blinatumomab |
front 28 What is the BBW of Blinatumomab? | back 28 1. CRS 2. Neurotoxicity |
front 29 Which agent is an anti-CD22 antibody? | back 29 Inotuzumab |
front 30 What is the BBW of Inotuzumab? | back 30 Hepatotoxicity QT prolongation |
front 31 Which agent is an anti-CD33 antibody? | back 31 Gemtuzumab |
front 32 Myelosuppression occurs in 100% of patients with which therapy? | back 32 Gemtuzumab |
front 33 BBW of Gemtuzumab | back 33 Hepatotoxicity Veno-occlusive disease |
front 34 Which agent is an anti CD52 antibody? | back 34 Alemtuzumab: |
front 35 Which agent can worsen thyroid gland disorders? | back 35 Alemtuzumab: |
front 36 BBW of Alemtuzumab: | back 36 Potentially lethal infusion reactions Autoimmune reactions |
front 37 Which agent is an anti CXCR4 antibody? | back 37 Plerixafor |
front 38 Which agent is an anti CD30 antibody? | back 38 Brentuximab vedotin |
front 39 Brentuximab vedotin is conjugated to what | back 39 MMAE |
front 40 Which mutations affect a protein whose activity is sufficient and necessary to cause neoplastic growth? | back 40 Driver mutations |
front 41 What is primary driver of pancreatic cancer? | back 41 KRAS |
front 42 Will Gefitinib work on KRAS? | back 42 No -RAS signaling pathway no longer needed input to signal and does not respond to receptor blockade |
front 43 What tumor suppressors are associated with hereditary breast and ovarian cancer? | back 43 BRCA1/BRCA2 |
front 44 What agent can be used for CML when imatinib no longer works due to clones that prevent binding? | back 44 Ponatinib |